Cerevance

Want to stay updated on the latest in #Parkinsons? Our Phase 2 #ClinicalTrial results for solengepras, featured in The Lancet's eClinicalMedicine, were published in an article by Parkinson's News Today. Read the full story here. https://lnkd.in/e4ximudK

We’re thrilled to announce the publication of our positive Phase 2 data from the clinical trial of solengepras for Parkinson’s disease in The Lancet's eClinicalMedicine. Check out the publication here: https://lnkd.in/eu4nxHZk

Thrilled to welcome, Dr. Sarah Sheikh to our Board of Directors. Her deep expertise in #neuroscience will be an invaluable asset as we continue to advance our mission of transforming the standard of care for CNS disorders. https://shorturl.at/map16

Our CEO, Craig Thompson, recently shared his insights during a panel at the #FierceBiotechSummit, where he discussed the future of #neuroscience innovation. We’re grateful for the opportunity to be a part of this important discussion. Learn more: https://lnkd.in/egyxTVTT

We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying?potential?novel therapeutic targets for patients with Alzheimer’s disease. A huge thank you to our dedicated team and partners at Merck for their hard work and commitment to excellence. Read the press release here: https://lnkd.in/eFFxkMgH

Our CEO, Craig Thompson, will be joining a panel at the upcoming #FierceBiotechSummit to discuss the latest in CNS drug discovery. https://lnkd.in/e2z9xrQ2

September is World Alzheimer’s Month, and today we recognize World Alzheimer’s Day. Throughout this month and beyond, we commend the resilience of individuals with Alzheimer’s disease as they navigate and overcome daily challenges.

Happy #LaborDay from all of us at Cerevance! Today, we celebrate the hard work, dedication, and passion of our incredible team. Your commitment drives our success and innovation every day. Thank you for all that you do!

What an inspiring and important story! Watch the latest episode of Bottom Line on BCTV to learn more about the impact of Parkinson's disease and the significant unmet treatment needs of those affected. The Cerevance team is committed to developing novel therapies for individuals with PD, and stories like this fuel our dedication to driving innovation and making a positive impact on patients.?https://lnkd.in/e-4hJepP

We are thrilled to welcome Dr. Sagar Vaidya, M.D., Ph.D., as our new Chief Medical Officer! In combination with a distinguished track record in advancing innovative therapeutic programs, Dr. Vaidya’s deep expertise in drug discovery and clinical research will support our mission of developing next-generation treatments to improve the lives of individuals with CNS disorders. To learn more about Dr. Vaidya and our novel approach to CNS therapies, read here:?https://lnkd.in/ex44Fjzd